Addressing the Exclusion of Pregnant Women and Data Gaps

The U.S. Food and Drug Administration (FDA) has released its final guidance on Postapproval Pregnancy Safety Studies, effective May 8, 2026. Historically, ethical concerns have led to the exclusion of pregnant women from clinical trials during new drug development. Consequently, at the time of market launch, there has been a significant lack of relevant safety data. This guideline aims to enhance the reliability of safety data for drug use during pregnancy by establishing clear criteria for post-approval studies. Ultimately, it seeks to protect patients by enabling the rapid updating of drug labels.

Presenting a Tripartite RWE Methodology

The FDA proposes three methodologies for collecting safety data: case reports, pregnancy registries, and supplementary studies utilizing real-world data (RWD). In particular, prospective observational studies in the form of registries, which enroll pregnant women before fetal outcomes are known, are emphasized as a key tool for reducing recall bias. Furthermore, the FDA encourages the mandatory parallel implementation of supplementary studies that integrate electronic health records (EHR) and insurance claims data to significantly improve data representativeness and analysis speed.

Biologics and UCB Cimzia: A Successful Precedent

UCB's Cimzia (certolizumab pegol), an autoimmune disease treatment targeting TNF-alpha, serves as a prime example of successful market differentiation through the effective use of pregnancy registries. Through the CRIB and CRADLE clinical studies, Cimzia demonstrated minimal placental transfer, and this information was incorporated into the FDA label, establishing it as a standard of care that pregnant women can use with confidence. With the establishment of this standard guideline, other biopharmaceutical companies are expected to actively pursue strategies to acquire post-approval safety data early and gain a marketing advantage, similar to Cimzia.

Growth of the RWE Market and Cost Reduction

The global real-world evidence (RWE) solutions market is projected to reach up to USD 6.2 billion by 2026, with continued double-digit annual growth. By designing studies in accordance with the FDA's standardized guidelines, pharmaceutical companies can reduce unnecessary trial-and-error and additional clinical costs, leading to significant savings in long-term post-market surveillance (PMS) costs. The accumulated RWE data enhances the credibility of drugs, directly leading to increased prescriptions, and ultimately contributing positively to the company's long-term financial performance.

Responding to Increased Regulatory Scrutiny

As the Prescription Drug User Fee Act (PDUFA VII) agreement requires more stringent demonstration of pregnancy safety, proactive measures by biopharmaceutical companies are necessary. Developers should design post-approval pregnancy safety study plans in advance of new drug application (NDA) submissions to prevent regulatory delays. With the availability of pregnancy data becoming a barrier to market entry, companies dealing with next-generation bioproducts should promptly establish RWE research infrastructure.